Obesity Advancements: Arrowhead’s RNAi Debut, Lilly’s $870M Bet, Novo’s Triple Exit & More
In this week’s Obesity Updates, we spotlight the latest breakthroughs and big pharma maneuvers reshaping the obesity treatment landscape—from next-gen RNAi approaches to long-acting GLP-1 deals and industry-wide narrative shifts.
Key updates include:
🧬 Arrowhead launches Phase 1/2a trial for ARO-ALK7 targeting fat metabolism via RNAi
💉 Metsera’s amylin analog delivers 8.4% placebo-adjusted weight loss in early trials
❌ Novo Nordisk halts development of its triple-hormone obesity drug over safety concerns
🔬 BioAge doubles down on APJ agonists that mimic exercise and boost muscle function
💰 Lilly inks $870M partnership with Camurus for monthly GLP-1-based therapies
🗣️ Novo Nordisk and OAC launch campaign reframing obesity as a chronic disease
Explore how leading innovators are rewriting the rules of obesity care through novel mechanisms, strategic alliances, and patient-centered advocacy.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1Therapies #RNAiTherapy #AmylinAnalog #ObesityTreatment #BiotechNews #LucidQuest #LillyPharma #NovoNordisk #ClinicalTrials #WeightLossScience #CardiometabolicHealth #APJAgonists #HealthcareInnovation